Takeda San Diego, Inc.

Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Phong H Vu

Jeffrey Alan Stafford

Anthony R Gangloff

Jerome C Bressi

Jason W Brown

Sheldon Cao

Nicholas Scorah

Andrew John Jennings

Mark Sabat

Haixia Wang

Xiao-Yi Xiao

Christopher Ronald Smith

John David Lawson

Junya Shirai

Xiaolun Wang

Tomohiro Okawa

Keiko Kakegawa

John S Tyhonas

Minoru Yoshida

Terufumi Takagi

Yasufumi Miyamoto

Akito Shibuya

Yuta Tanaka

Rei Okamoto

Joanne Miura

Zenyu Shiokawa

Nobuyuki Matsunaga

Yoichi Nishikawa

Yoshito Terao

Lily Kwok

Takafumi Yukawa

Mallareddy Komandla

Takeshi Yoshikawa

Takashi Nakahata

Hiroki Takahagi

Paul Tanis

Stephen W Kaldor

Steven John Woodhead

Robert J Skene

Walter Keung

Steve Swann

Simone Bigi

Christopher Smith

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.

Pyridinyl and fused pyridinyl triazolone derivatives

Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.

Heteroarylamide inhibitors of TBK1

Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

Poly (ADP-ribose) polymerase (PARP) inhibitors

Compounds, pharmaceutical compositions, kits and methods useful for inhibiting HDAC, thereby treating a disease state for which HDAC possess activity that contributes to the pathology and/or symptomology of the disease state. The compound is selected from the group consisting of: 

Histone deacetylase inhibitors

Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formulae: wherein the variables are as defined herein.

Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R, R, Rand Rare each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained Calkyl, Caminoalkyl or Coxaalkyl, and a substituted and unsubstituted 3, 4, 5, 6, 7 or 8 membered ring, with the proviso that Rand Rare not both hydrogen; Ris selected from the group consisting of a carbonyl, a substituted or unsubstituted Calkyl, a substituted or unsubstituted &#x2014;Calkyl-C(O), a substituted or unsubstituted &#x2014;C(O)&#x2014;Calkyl, and a substituted or unsubstituted &#x2014;C(O)C(O)Calkyl; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 3-12 atoms connecting the M substituent to the carbon atom alpha to the L substituent.

Compounds that may be used to inhibit histone deacetylase having the formulaZ-Q-L-M or Z-L-Mwherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

Compounds that may be used to inhibit histone deacetylase having the formulaZ-Q-L-M or Z-L-Mwherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0&#x2013;10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

Histone deacetylase inhibitors and uses thereof are provided that have the general formula 

Growing community of inventors

San Diego, CA, United States of America

Phong H Vu